Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease
Forskningsoutput: Tidskriftsbidrag › Översiktsartikel
Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, noncontinuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available nonoral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.
|Enheter & grupper|
Ämnesklassifikation (UKÄ) – OBLIGATORISK
|Tidskrift||Journal of Parkinson's Disease|
|Status||Published - 2018|
|Peer review utförd||Ja|